BIOPX vs. FPHAX
Compare and contrast key facts about Baron Opportunity Fund (BIOPX) and Fidelity Select Pharmaceuticals Portfolio (FPHAX).
BIOPX is managed by Baron Capital Group, Inc.. It was launched on Feb 29, 2000. FPHAX is managed by Fidelity. It was launched on Jun 17, 2001.
Scroll down to visually compare performance, riskiness, drawdowns, and other indicators and decide which better suits your portfolio: BIOPX or FPHAX.
Key characteristics
| BIOPX | FPHAX | |
|---|---|---|
| YTD Return | 36.45% | 14.92% |
| 1Y Return | 46.50% | 21.57% |
| 3Y Return (Ann) | -1.16% | 2.96% |
| 5Y Return (Ann) | 15.59% | 5.07% |
| 10Y Return (Ann) | 9.82% | 3.59% |
| Sharpe Ratio | 2.22 | 1.28 |
| Sortino Ratio | 2.85 | 1.88 |
| Omega Ratio | 1.40 | 1.22 |
| Calmar Ratio | 1.32 | 1.39 |
| Martin Ratio | 12.18 | 4.90 |
| Ulcer Index | 3.81% | 4.05% |
| Daily Std Dev | 20.86% | 15.48% |
| Max Drawdown | -67.79% | -37.34% |
| Current Drawdown | -4.90% | -14.25% |
Correlation
The correlation between BIOPX and FPHAX is 0.62, which is considered to be moderate. This suggests that the two assets have some degree of positive relationship in their price movements. Moderate correlation can be acceptable for portfolio diversification, offering a balance between risk and potential returns.
Performance
BIOPX vs. FPHAX - Performance Comparison
In the year-to-date period, BIOPX achieves a 36.45% return, which is significantly higher than FPHAX's 14.92% return. Over the past 10 years, BIOPX has outperformed FPHAX with an annualized return of 9.82%, while FPHAX has yielded a comparatively lower 3.59% annualized return. The chart below displays the growth of a $10,000 investment in both assets, with all prices adjusted for splits and dividends.
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
BIOPX vs. FPHAX - Expense Ratio Comparison
BIOPX has a 1.31% expense ratio, which is higher than FPHAX's 0.75% expense ratio.
Risk-Adjusted Performance
BIOPX vs. FPHAX - Risk-Adjusted Performance Comparison
This table presents a comparison of risk-adjusted performance metrics for Baron Opportunity Fund (BIOPX) and Fidelity Select Pharmaceuticals Portfolio (FPHAX). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Dividends
BIOPX vs. FPHAX - Dividend Comparison
BIOPX has not paid dividends to shareholders, while FPHAX's dividend yield for the trailing twelve months is around 0.74%.
| TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
BIOPX Baron Opportunity Fund | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
FPHAX Fidelity Select Pharmaceuticals Portfolio | 0.74% | 0.63% | 1.33% | 1.17% | 1.31% | 1.31% | 1.44% | 1.33% | 1.07% | 5.59% | 5.81% | 11.12% |
Drawdowns
BIOPX vs. FPHAX - Drawdown Comparison
The maximum BIOPX drawdown since its inception was -67.79%, which is greater than FPHAX's maximum drawdown of -37.34%. Use the drawdown chart below to compare losses from any high point for BIOPX and FPHAX. For additional features, visit the drawdowns tool.
Volatility
BIOPX vs. FPHAX - Volatility Comparison
Baron Opportunity Fund (BIOPX) has a higher volatility of 5.78% compared to Fidelity Select Pharmaceuticals Portfolio (FPHAX) at 4.58%. This indicates that BIOPX's price experiences larger fluctuations and is considered to be riskier than FPHAX based on this measure. The chart below showcases a comparison of their rolling one-month volatility.